Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19

References

• Stricker RB, Fesler MC. A novel plan to deal with SARS-CoV-2 and COVID-19 disease. J Med Virol. 2020;92:1394–1395. doi:10.1002/jmv.25945
   Web of Science ®Google Scholar
• Santarpia JL, Herrera VL, Rivera DN, et al. The infectious nature of patient-generated SARS-CoV-2 aerosol. MedRxiv. 2020. doi:10.1101/2020.07.13.20041632
   Google Scholar
• Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA. 2020;323(21):2195. doi:10.1001/jama.2020.720232329797
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March–June 2020. MMWR. 2020;69:993.32730238
   PubMed Web of Science ®Google Scholar
• Bauchner H, Fontanarosa P. Thinking of risk in the era of COVID-19. JAMA. 2020;324(2):151. doi:10.1001/jama.2020.1024232496528
   PubMed Web of Science ®Google Scholar
• Torales J, O’Higgins M, Castaldelli-Maia JM, Ventriglio A. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry. 2020;66:317–320. doi:10.1177/002076402091521232233719
   PubMed Web of Science ®Google Scholar
• Lee BY. Coronavirus medical costs could soar into hundreds of billions as more Americans become infected. The Conversation 2020 Available from: https://theconversation.com/coronavirus-medical-costs-could-soar-into-hundreds-of-billions-as-more-americans-becomeinfected-137479. Accessed 85, 2020.
   Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020.  doi:10.1038/s41586-020-2798-3
   Google Scholar
• Farkas C, Fuentes-Villalobos F, Garrido JL, Haigh J, Barría MI. Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions. PeerJ. 2020;8:e9255. doi:10.7717/peerj.925532509472
   PubMed Web of Science ®Google Scholar
• Pollan M, Perez-Gomez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535–544. doi:10.1016/S0140-6736(20)31483-532645347
   PubMed Web of Science ®Google Scholar
• Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020;80(6):e32–e33. doi:10.1016/j.jinf.2020.03.02732209383
   PubMed Web of Science ®Google Scholar
• Hillis A, Germain J, Hope V, McVeigh J, Van Hout MC. Pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM): a scoping review on PrEP service delivery and programming. AIDS Behav. 2020;24(11):3056–3070. doi:10.1007/s10461-020-02855-932274670
   PubMed Web of Science ®Google Scholar
• Dousa KM, Malavade SS, Furin J, et al. SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: implications for prophylaxis. IDCases. 2020;20:e00778. doi:10.1016/j.idcr.2020.e0077832341910
   PubMed Web of Science ®Google Scholar
• Kass DA. COVID-19 and severe obesity: a big problem? Ann Intern Med. 2020. doi:10.7326/M20-5677
   Web of Science ®Google Scholar
• Steensels D, Oris E, Coninx L, et al. Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium. JAMA. 2020;324(2):195–197. doi:10.1001/jama.2020.1116032539107
   PubMed Web of Science ®Google Scholar
• Nguyen LH, Drew DA, Graham MS, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5(9):e475–e483. doi:10.1016/S2468-2667(20)30164-X32745512
   PubMed Web of Science ®Google Scholar
• Gaffney AW, Himmelstein D, Woolhandler S. Risk for severe COVID-19 illness among teachers and adults living with school-aged children. Ann Intern Med. 2020. doi:10.7326/M20-5413
   Web of Science ®Google Scholar
• Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection. A narrative review. Ann Intern Med. 2020;173(5):362–367. doi:10.7326/M20-301232491919
   PubMed Web of Science ®Google Scholar
• Zeberg H, Pääbo S.The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020. doi:10.1038/s41586-020-2818-3.
   Google Scholar
• Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738. doi:10.1016/j.tmaid.2020.10173832387409
   PubMed Web of Science ®Google Scholar
• Risch HA. Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped-up immediately as key to the pandemic crisis. Am J Epidemiol. 2020. doi:10.1093/aje/kwaa093
   Web of Science ®Google Scholar
• Jain R, Danziger LH. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Design. 2004;10:3045–3053. doi:10.2174/1381612043383322
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc. 2020;95:1213–1221. doi:10.1016/j.mayocp.2020.03.02432359771
   PubMed Web of Science ®Google Scholar
• Yu B, Li C, Chen P, Li J, Jiang H, Wang DW. Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs. Sci China Life Sci. 2020. doi:10.1007/s11427-020-1782-1
   Web of Science ®Google Scholar
• Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents. 2020;55(6):105988. doi:10.1016/j.ijantimicag.2020.10598832305587
   PubMed Web of Science ®Google Scholar
• Ducharme J, Fieger H, Ducharme MP, Khalil SK, Wainer IW. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol. 1995;40:127–133. doi:10.1111/j.1365-2125.1995.tb05768.x8562294
   PubMed Web of Science ®Google Scholar
• Lim HS, Im JS, Cho JY, et al. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax. Antimicrob Agents Chemother. 2009;53:1468–1475. doi:10.1128/AAC.00339-0819188392
   PubMed Web of Science ®Google Scholar
• Im JH, Huh K, Yoon CG, et al. Malaria control and chemoprophylaxis policy in the Republic of Korea Armed Forces for the previous 20 years (1997–2016). Malaria J. 2018;17:295. doi:10.1186/s12936-018-2449-4
   Web of Science ®Google Scholar
• Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: an old drug with new relevance. Cleveland Clin J Med. 2018;85:459–467. doi:10.3949/ccjm.85a.17034
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739. doi:10.1093/cid/ciaa23732150618
   PubMed Web of Science ®Google Scholar
• Spinelli FR, Ceccarelli F, Di Franco M, et al. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann Rheum Dis. 2020;79:666–668. doi:10.1136/annrheumdis-2020-21736732241791
   PubMed Web of Science ®Google Scholar
• Adegboye OA, Adekunle AI, Gayawan E. Early transmission dynamics of novel coronavirus (COVID-19) in Nigeria. Int J Environ Res Public Health. 2020;17(9):pii: E3054. doi:10.3390/ijerph17093054
   Web of Science ®Google Scholar
• Quaresima V, Naldini MM, Cirillo DM. The prospects for the SARS-CoV-2 pandemic in Africa. EMBO Mol Med. 2020;12. doi:10.15252/emmm.202012488
   Web of Science ®Google Scholar
• Lofgren SM, Nicol MR, Bangdiwala AS, et al. Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19. MedRxiv. 2020. doi:10.1101/2020.07.16.20155531
   Google Scholar
• Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214:273.e1–273.e8. doi:10.1016/j.ajog.2015.09.078
   Web of Science ®Google Scholar
• Braun S, Ferner M, Kronfeld K, Griese M. Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases. Pediatr Pulmonol. 2015;50:410–419. doi:10.1002/ppul.2313325491573
   PubMed Web of Science ®Google Scholar
• Park JJH, Decloedt EH, Rayner CR, Cotton M, Mills EJ. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. Lancet Glob Health. 2020;8(10):e1249–e1250. doi:10.1016/S2214-109X(20)30365-X32828171
   PubMed Web of Science ®Google Scholar
• Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clin Pharmacol Ther. 2020;108(4):766–769. doi:10.1002/cpt.187432344449
   PubMed Web of Science ®Google Scholar
• Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, coronavirus disease 2019, and QT prolongation. JAMA Cardiol. 2020;5(9):986. doi:10.1001/jamacardio.2020.178232936259
   PubMed Web of Science ®Google Scholar
• Bhattacharya R, Chowdhury S, Mukherjee R, et al. Pre exposure hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers. MedRxiv. 2020. doi:10.1101/2020.06.09.20116806
   Google Scholar
• Chatterjee P, Anand T, Singh KJ, et al. Healthcare workers and SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19. Indian J Med Res.2020;151(5):459-467.doi:10.4103/ijmr.IJMR_2234_20.
   Web of Science ®Google Scholar
• Khurana A, Kaushal GP, Gupta R, Verma V, Sharma K, Kohli M. Prevalence and clinical correlates of COVID-19 outbreak among health care workers in a tertiary level hospital in Delhi. MedRxiv. 2020. doi:10.1101/2020.07.21.20159301
   Google Scholar
• Zhong J, Shen G, Yang H, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol. 2020;2(9):e557–e564. doi:10.1016/S2665-9913(20)30227-732838309
   PubMedGoogle Scholar
• Ferreira A, Oliveira-e-Silva A, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. MedRxiv. 2020. doi:10.1101/2020.06.26.20056507
   Google Scholar
• Ip A, Ahn J, Zhou Y, et al. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. MedRxiv. 2020. doi:10.1101/2020.08.20.20178772
   Google Scholar
• Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ II. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol 2020.doi:10.1016/S2665-9913(20)30305-2.
   Google Scholar
• Rosenke K, Jarvis MA, Feldmann F, et al. Hydroxychloroquine proves ineffective in hamsters and macaques infected with SARS- CoV-2. BioRxiv. 2020. doi:10.1101/2020.06.10.145144
   Google Scholar
• Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020;585(7826):584–587. doi:10.1038/s41586-020-2558-432698191
   PubMed Web of Science ®Google Scholar
• O’Neill WW. Will hydroxychloroquine impede or prevent COVID-19 (WHIP COVID-19). 2020 Available from: https://clinicaltrials.gov/ct2/show/NCT4341441?term=whip&cond=coronavirus&cntry=US&draw=2&rank=1. NLM identifier: NCT4341441. Accessed 83, 2020.
   Google Scholar
• Wright JK, Tan DHS, Walmsley SL, et al. Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: a structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada. Trials. 2020;21:647. doi:10.1186/s13063-020-04577-832665039
   PubMed Web of Science ®Google Scholar
• Hazan S A study of hydroxychloroquine, vitamin C, vitamin D, and zinc for the prevention of COVID-19 infection (HELPCOVID-19). 2020 Available from: https://www.clinicaltrials.gov/ct2/show/NCT4335084?term=Progenabiome&cond=COVID19&draw=2&rank=4. NLM identifier: NCT4335084. Accessed 925, 2020.
   Google Scholar
• Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Rev Anti Infect Ther. 2020. doi:10.1080/14787210.2020.1799785
   Web of Science ®Google Scholar
• Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: A randomized clinical trial. JAMA Intern Med 2020. doi:10.1001/jamainternmed.2020.6319.
   Google Scholar
• Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML,et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. MedRxiv. 2020. doi:10.1101/2020.09.18.20197327
   Google Scholar
• Pham Q, Wikjer D, Cafazzo JA, Eng P. Beyond the randomized controlled trial: a review of alternatives in mHealth clinical trial methods. JMIR Mhealth Uhealth. 2016;4:e107. doi:10.2196/mhealth.572027613084
   PubMed Web of Science ®Google Scholar
• Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006;367:1319–1327. doi:10.1016/S0140-6736(06)68578-416631910
   PubMed Web of Science ®Google Scholar
• Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.2904
   Web of Science ®Google Scholar
• Song P, Karako T. COVID-19: real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends. 2020;14:1–2. doi:10.5582/bst.2020.0105632092748
   PubMed Web of Science ®Google Scholar
• Schlagenhauf P, Hatz C, Behrens R, et al. Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. Travel Med Infect Dis. 2015;13:192–196. doi:10.1016/j.tmaid.2015.03.01025825015
   PubMed Web of Science ®Google Scholar
• Fan HH, Wang LQ, Liu WL, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chin Med J (Engl). 2020;133(9):1051–1056. doi:10.1097/CM9.000000000000079732149769
   PubMed Web of Science ®Google Scholar
• Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;177:104760. doi:10.1016/j.antiviral.2020.10476032135219
   PubMed Web of Science ®Google Scholar
• Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. doi:10.1016/j.antiviral.2020.10478732251768
   PubMed Web of Science ®Google Scholar
• Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob 2020;19(1):23. doi:10.1186/s12941-020-00368-w
   Google Scholar
• Rajter JC, Sherman M, Fatteh N, Vogel F, Sacks J, Rajter JJ. ICON (Ivermectin in COvid Nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. MedRxiv. 2020. doi:10.1101/2020.06.06.20124461
   Google Scholar
• Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors’ responses. Antiviral Res. 2020;178:104805. doi:10.1016/j.antiviral.2020.10480532330482
   PubMed Web of Science ®Google Scholar
• Baudou E, Lespine A, Durrieu G, et al. Serious ivermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med. 2020;383:787–789. doi:10.1056/NEJMc191734432813957
   PubMed Web of Science ®Google Scholar
• Alshaban F. A recommendation for the use of chloroquine, hydroxychloroquine, primaquine, or tafenoquine for prophylaxis against the 2019 novel coronavirus (COVID-19) with note to the ophthalmic considerations. Eye Res. 2020;6:S7–S10. doi:10.16964/er.v6i1.99
   Google Scholar
• Dow GS, Luttick A, Fenner J, Wesche D, Yeo KR, Rayner C. Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro. BioRxiv. 2020. doi:10.1101/2020.07.12.199059
   Google Scholar
• Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy – a cohort study. Ann Intern Med. 2020. doi:10.7326/M20-3689
   Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130:1545–1548. doi:10.1172/JCI13800332167489
   PubMed Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. A randomized clinical trial. JAMA. 2020;324(5):460. doi:10.1001/jama.2020.1004432492084
   PubMed Web of Science ®Google Scholar
• Liu M, Chen Z, Dai M-Y, et al. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19. Transfusion. 2020:1–7. doi:10.1111/trf.1597531898351
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–456. doi:10.1038/s41586-020-2571-732698192
   PubMed Web of Science ®Google Scholar
• Ledford H. Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit? Nature. 2020;584(7821):333–334. doi:10.1038/d41586-020-02360-y32782402
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N, Leung CC, Migliori GB. Universal use of face masks for success against COVID-19: evidence and implications for prevention policies. Eur Respir J. 2020;55:2001260. doi:10.1183/13993003.01260-202032350103
   PubMed Web of Science ®Google Scholar
• Schünemann HJ, Akl EA, Chou R, et al. Use of facemasks during the COVID-19 pandemic. Lancet Respir Med. 2020. doi:10.1016/S2213-2600(20)30352-0
   Web of Science ®Google Scholar
• Gandhi M, Rutherford GW. Facial masking for Covid-19 — potential for “variolation” as we await a vaccine. N Engl J Med. 2020. doi:10.1056/NEJMp2026913
   Google Scholar